Dr Reddy’s Q4 net profits grow multifold driven by good India and US performance
Live MintDr Reddy’s Laboratories Ltd reported net profits for the March quarter at ₹959.2 Crore grew more nine folds from ₹99.6 Crore in the year-old quarter on a favorable base. The company’s performance in other markets as India, Europe also supported overall show, even though Emerging markets sales did see some decline. Europe sales at Rs 496 Crore though also grew 12% year-on-year helped by new product launches, traction in base business volumes, Emerging market sales however declined 7% year-on-year to ₹1114.2 Crore led by declining Russia revenues while Romania and CIS business revenues remained flat. The Revlimid generics that helped drive year-on-year growth for US sales during the quarter, however, were expected to see some decline sequentially as per analysts, due to competition entering, post the end of 180-day exclusivity.